Skip to main content

Detail

Alexandra Kautzky-Willer
Univ.-Prof. Dr. Alexandra Kautzky-WillerInterim head of the Department of Internal Medicine III and the Division of Endocrinology and Metabolism. Head of the Gender Medicine Unit and the University Course Gender Medicine.

Department of Medicine III (Division of Endocrinology and Metabolism)
Position: Professor

ORCID: 0000-0002-3520-4105
T +43 1 40400 22280
alexandra.kautzky-willer@meduniwien.ac.at

Further Information

Keywords

-gender differences; Diabetes Mellitus; Metabolic Syndrome X; Obesity; Sex

Research group(s)

Research interests

  • Endocrinology
  • Gestational diabetes and fetal programming
  • Gender aspects of obesity
  • Gender aspects of metabolic syndrome
  • Gender aspects of type 2 diabetes
  • Gender aspects of type 1 diabetes/autoimmunity
  • Gender aspects of insulin resistance and beta cell function: Changes in pathogenesis of and interaction with different disease processes
  • Gender aspects of inflammation, adipokines, endothelial dysfunction

Techniques, methods & infrastructure

- Functional tests, insulin sensitivity, insulin secretion, incretins;
- Glucose monitoring
- Minimal modeling
- Spectroscopy

Grants

  • GOING-FWD Gender Outcomes INternational Group: to Further Well-being Development (2019)
    Source of Funding: FWF (Austrian Science Fund), GENDER-NET Plus ERA-NET Cofund
    Principal Investigator
  • Optimal gender-specific treatment paths on healthcare multiplex networks (2017)
    Source of Funding: WWTF (Vienna Science and Technology Fund), Mathematics and…
    Principal Investigator
  • Epigenetik-basierte Typ-2-Diabetes Diagnostik aus Speichel und Blut (2015)
    Source of Funding: FFG (Austrian Research Promotion Agency), FEMtech
    Principal Investigator
  • DIABgender: Gender-specific Diabetes Self-management (2014)
    Source of Funding: FFG (Austrian Research Promotion Agency), FEMtech FTI
    Principal Investigator
  • DALI: Vitamin D and lifestyle intervention for gestational diabetes mellitus (GDM) prevention (2010)
    Source of Funding: EU, FP7
    Principal Investigator

Selected publications

  1. Kautzky-Willer, A. & Harreiter, J., 2019. The wave of sweetness and obesity continues. Nature Reviews Endocrinology, 15(1), pp.6-8. Available at: http://dx.doi.org/10.1038/s41574-018-0119-9.
  2. Kautzky-Willer, A., Harreiter, J. & Pacini, G., 2016. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. Endocrine Reviews, 37(3), pp.278-316. Available at: http://dx.doi.org/10.1210/er.2015-1137.
  3. Kautzky-Willer, A., Thurner, S. & Klimek, P., 2016. Use of statins offsets insulin-related cancer risk. Journal of Internal Medicine, 281(2), pp.206-216. Available at: http://dx.doi.org/10.1111/joim.12567.
  4. Harreiter, J. et al., 2016. IADPSG and WHO 2013 Gestational Diabetes Mellitus Criteria Identify Obese Women With Marked Insulin Resistance in Early Pregnancy: Table 1. Diabetes Care, 39(7), pp.e90-e92. Available at: http://dx.doi.org/10.2337/dc16-0200.
  5. Owens, D.R. et al., 2017. Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100�U/mL added to oral antidiabetes agents in type 2 diabetes. Diabetes, Obesity and Metabolism. Available at: http://dx.doi.org/10.1111/dom.12966.